21278-85-3

Basic information

• Product Name: 2-(4-pyridinyl)-4-thiazolecarboxylic acid ethyl ester
• Synonyms: 2-(4-pyridinyl)-4-thiazolecarboxylic acid ethyl ester;ethyl 2-(pyridin-4-yl)thiazole-4-carboxylate
• CAS NO: 21278-85-3
• Molecular Formula: C₁₁H₁₀N₂O₂S
• Molecular Weight: 234.28
• Mol File: 21278-85-3.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(4-pyridinyl)-4-thiazolecarboxylic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-pyridinyl)-4-thiazolecarboxylic acid ethyl ester(21278-85-3)
• EPA Substance Registry System: 2-(4-pyridinyl)-4-thiazolecarboxylic acid ethyl ester(21278-85-3)

Safety Data

• Hazardous Substances Data: 21278-85-3(Hazardous Substances Data)

Usage

Heterocyclic compound

Yes, it contains both nitrogen and sulfur atoms in its ring structure.

Ethyl ester derivative

Yes, it is derived from 2-(4-pyridinyl)-4-thiazolecarboxylic acid by attaching an ethoxy group to the carboxyl group.

Potential pharmaceutical applications

Yes, it has been studied for its potential as an antimicrobial and antifungal agent.

Potential as a precursor for the synthesis of other biologically active compounds

Yes, it can be used as a building block in the synthesis of other organic molecules.

Potential use as a ligand in coordination chemistry

Yes, it has been investigated for its ability to bind to metal ions.

Versatile compound

Yes, it has potential applications in medicinal chemistry, pharmaceuticals, and materials science.

Upstream product

• 15933-07-0 Ethyl 2-oxobutanoate 
• 2196-13-6 pyridine-4-carbothioamide 
• 70-23-5 ethyl Bromopyruvate 

Downstream Products

• 533885-37-9 2-(4-pyridinyl)-1,3-thiazole-4-carbaldehyde 
• 21278-93-3 2-pyridin-4-yl-thiazole-4-carboxylic acid N'-(toluene-4-sulfonyl)-hydrazide 
• 21278-90-0 2-pyridin-4-yl-thiazole-4-carboxylic acid (4-nitro-benzylidene)-hydrazide 
• 21278-91-1 2-pyridin-4-yl-thiazole-4-carboxylic acid (4-hydroxy-3-methoxy-benzylidene)-hydrazide 
• 21278-92-2 2-pyridin-4-yl-thiazole-4-carboxylic acid [1-(4-amino-phenyl)-ethylidene]-hydrazide 
• 21278-89-7 1-Furfuryliden-2-<2-(pyridyl-4)-thiazolyl-4-carbonyl>-hydrazin 
• 321429-91-8 N-(3''-dimethylaminopropyl)-2-(pyridin-4'-yl)thiazole-4-carboxamide 
• 21278-86-4 2-(4-Pyridyl)-1,3-thiazole-4-carboxylic acid 

Relevant articles and documents

Discovery of Novel Aryl Carboxamide Derivatives as Hypoxia-Inducible Factor 1α Signaling Inhibitors with Potent Activities of Anticancer Metastasis

In order to discover novel hypoxia-inducible factor 1 (HIF-1) inhibitors for the cancer metastasis treatment, 68 new aryl carboxamide compounds were synthesized and evaluated for their inhibitory effect by dual luciferase-reporter assay. Based on five rounds of investigation on structure-activity relationships step by step, compound 30m was discovered as the most active inhibitor (IC50 = 0.32 μM) with no obvious cytotoxicity (CC50 > 50 μM). It effectively attenuated hypoxia-induced HIF-1α protein accumulation and reduced transcription of vascular epidermal growth factor in a dose-dependent manner, which was further demonstrated by its inhibitory potency on capillary-like tube formation, angiogenesis of zebrafish as well as cellular migration and invasion. Importantly, compound 30m exhibited antimetastatic potency in breast cancer lung metastasis in the mice model, indicating its promising therapeutic potential for prevention and treatment of tumor metastasis. These results definitely merit attention for further rational design of more efficient HIF-1 inhibitors in the future.

HIV PROTEASE INHIBITING COMPOUNDS

A compound of the formula (I) is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.

2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use

Selected compounds are effective for treatment of diseases, such as cell proliferation or apoptosis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving stroke, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.